
Opinion|Videos|December 8, 2023
Expert Insights in Overcoming Endocrine Resistance for Patients With ER+/HER2- Metastatic Breast Cancer
Author(s)Hope S. Rugo, MD
Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















